Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD70-Targeted [<sup>18</sup>F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Same author

Trends in cancer imaging.

Trends in cancer·2024

Same author

Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.

MedChemComm·2019

Same author

A systematic analysis of the association between Notch1 expression and the patients with digestive tract cancers.

Biomarkers in medicine·2018

Same author

Occurrence and regression of BK polyomavirus associated carcinoma: a clinical and next-generation sequencing study.

Clinical science (London, England : 1979)·2018

Same author

Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma.

Molecular oncology·2018

Search research articles

Related Experiment Video

Updated: Jan 17, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

CD70-Targeted Radiotheranostics: Now and Future.

Binyu Shi¹, Xinyuan Zhou¹, Junjun Zhou²

¹Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Seminars in Nuclear Medicine

|September 19, 2025

Summary

This summary is machine-generated.

Cluster of differentiation 70 (CD70) is overexpressed in cancers. CD70-targeted radiotheranostics show promise for cancer treatment, addressing limitations of current therapies like antibody-drug conjugates and CAR-T cells.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jan 17, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

Oncology
Radiochemistry
Immunotherapy

Background:

Cluster of differentiation 70 (CD70) is a TNF superfamily member, overexpressed in malignancies like ccRCC and NPC.
CD70 acts as a ligand for the co-stimulatory receptor CD27.
Current therapies (ADCs, CAR-T) face challenges like drug resistance and poor tumor penetration.

Purpose of the Study:

To review CD70 expression in normal and tumor tissues.
To highlight CD70-targeted immuno-PET/CT imaging results.
To discuss therapeutic radiopharmaceuticals for future CD70-targeted radiotheranostics development.

Main Methods:

Literature review of CD70 expression.
Analysis of clinical trial data for immuno-PET/CT imaging.
Survey of preclinical and clinical therapeutic radiopharmaceuticals.

Main Results:

CD70 is aberrantly expressed in various cancers.
Clinical trials show promising results for CD70-targeted immuno-PET/CT imaging.
Several therapeutic radiopharmaceuticals are in development.

Conclusions:

CD70-targeted radiotheranostics offer a potential solution to current therapy limitations.
Immuno-PET/CT imaging demonstrates clinical utility.
Further development of radiotheranostics is warranted for clinical application.